Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             215 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 172 A case for development of stereotactic ablative body radiotherapy (SABR) for lung cancer at Aberdeen Stilwell, C.
 2013
 79 S1 p. S58-S59
2 p.
 artikel
2 13 Acquired resistance to EGFR inhibition: evolution from adenocarcinoma to small cell lung cancer (SCLC) Moss, C.
 2013
 79 S1 p. S5-
1 p.
 artikel
3 150 A “fast track” system providing CT planned radiotherapy Maguire, J.
 2013
 79 S1 p. S51-
1 p.
 artikel
4 30 Afatanib use in non-small cell cancer patients whose tumours have been previously sensitive to EGFR inhibitors: the UK Named Patient Use experience Khan, F.
 2013
 79 S1 p. S10-S11
2 p.
 artikel
5 175 An assessment of patient intrafraction motion for lung SABR using VMAT Moore, K.
 2013
 79 S1 p. S60-
1 p.
 artikel
6 40 An audit and service evaluation of non-small cell lung cancer – assessing the outcome of PS2 patients receiving first line chemotherapy Tay, J.
 2013
 79 S1 p. S14-
1 p.
 artikel
7 156 An audit of the quality of curative intent NSCLC radiotherapy Jellett, L.
 2013
 79 S1 p. S52-S53
2 p.
 artikel
8 196 An observational study of the use of indwelling pleural catheters for malignant pleural effusions – The Cambridge Pleural Unit experience Pulimood, T.
 2013
 79 S1 p. S68-
1 p.
 artikel
9 186 A phase I/II trial of concurrent chemo-radiation with dose-escalated radiotherapy in patients with stage II or stage III non-small cell lung cancer Landau, D.B.
 2013
 79 S1 p. S64-S65
2 p.
 artikel
10 111 A referral pro-forma can reduce time from surgical resection to adjuvant chemotherapy for NSCLC patients Sriskandarajah, S.
 2013
 79 S1 p. S38-S39
2 p.
 artikel
11 148 A retrospective study of changing performance status and staging in all patients presenting with lung cancer to the Northern Health and Social Care Trust over the past decade McShane, A.
 2013
 79 S1 p. S50-
1 p.
 artikel
12 94 A review of the management of mesothelioma patients who received second line chemotherapy within the Kent Oncology Centre Network Shiarli, A.
 2013
 79 S1 p. S33-
1 p.
 artikel
13 39 Are we ageist? The impact of patient age on chemotherapy treatment decisions in advanced non-small cell lung cancer at St James's Institute of Oncology Kelly, J.
 2013
 79 S1 p. S13-S14
2 p.
 artikel
14 20 A single centre experience of erlotinib in unselected and wild type EGFR patients with non small cell lung cancer Walter, H.S.
 2013
 79 S1 p. S7-
1 p.
 artikel
15 19 A single centre experience of gefitinib in patients with EGFR mutation positive non small cell lung cancer Walter, H.S.
 2013
 79 S1 p. S7-
1 p.
 artikel
16 173 Assessing CT changes post stereotactic ablative body radiotherapy (SABR) using the criteria proposed by Senan et al. Robinson, H.
 2013
 79 S1 p. S59-
1 p.
 artikel
17 140 Assessment and impact of sarcopenia in lung cancer: a systematic review highlighting implications for research and clinical practice Collins, J.
 2013
 79 S1 p. S47-
1 p.
 artikel
18 17 Assessment of epidermal growth factor (EGFR) mutations in patients with NSCLC – a single institution experience Jordan, E.J.
 2013
 79 S1 p. S6-
1 p.
 artikel
19 208 Attitudes to risk associated with lung cancer – Plan for a qualitative study Powell, H.A.
 2013
 79 S1 p. S72-
1 p.
 artikel
20 26 Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation Douglas, R.
 2013
 79 S1 p. S9-
1 p.
 artikel
21 34 Audit of management of neutropenic sepsis in adults receiving systemic anticancer therapy within Belfast Health and Social Care Trust Mckew, J.R.
 2013
 79 S1 p. S12-
1 p.
 artikel
22 155 Audit of set-up variation using On Board kV Imaging in patients undergoing radical radiotherapy (RT) for non-small cell lung cancer (NSCLC) Hyde, K.
 2013
 79 S1 p. S52-
1 p.
 artikel
23 126 Audit of the SPARC holistic needs assessment tool for patients with lung cancer, 2011–2012 Roberts, J.
 2013
 79 S1 p. S43-
1 p.
 artikel
24 204 Audit on lung cancer surgical cases in Northern Ireland Jama, F.
 2013
 79 S1 p. S70-S71
2 p.
 artikel
25 Author index 2013
 79 S1 p. S75-S80
6 p.
 artikel
26 46 Blood transfusion requirements of NSCLC patients receiving chemotherapy in the BTOG2 trial Best, J.
 2013
 79 S1 p. S15-S16
2 p.
 artikel
27 76 Cancer of unknown primary presenting as pleural effusion – A review of 620 patients in Taunton Musgrove Park Hospital Burley, K.
 2013
 79 S1 p. S27-
1 p.
 artikel
28 80 Can stair assessment be standardised? A different and interesting approach to this simple test Jama, F.
 2013
 79 S1 p. S28-
1 p.
 artikel
29 131 Caring for patients with lung cancer in the acute hospital setting; experiences from registered nurses perspectives Sabel, L.M.
 2013
 79 S1 p. S44-S45
2 p.
 artikel
30 99 Case report: malignant peritoneal mesothelioma Cormack, S.
 2013
 79 S1 p. S34-S35
2 p.
 artikel
31 214 Changing paradigm in surgical management of broncho pulmonary carcinoids: A 7 year single institutional experience Balasubramanian, V.
 2013
 79 S1 p. S74-
1 p.
 artikel
32 6 Circulating tumour cells in NSCLC. Enumeration and analysis using VitaAssay and Screencell techniques O'Flaherty, J.
 2013
 79 S1 p. S2-S3
2 p.
 artikel
33 11 Clinical audit of non-squamous NSCLC patients in reference to sampling technique, adequacy of sample for immunohistochemistry and EGFR analysis Qasim, M.
 2013
 79 S1 p. S4-
1 p.
 artikel
34 177 Clinical implementation of stereotactic ablative radiotherapy (SABR) for NSCLC in the UK Baker, A.
 2013
 79 S1 p. S61-
1 p.
 artikel
35 185 Comparative evaluation of gemcitabine/carboplatin and cisplatin/etoposide with concurrent chemoradiation in locally advanced non small cell carcinoma lung cancer in terms of response and toxicities Roshan, V.
 2013
 79 S1 p. S64-
1 p.
 artikel
36 153 Comparison of PTV geometrics and toxicity between 4DCT and 3DCT for radical treatment of lung cancer: Northern Ireland experience O'Hare, J.
 2013
 79 S1 p. S52-
1 p.
 artikel
37 183 Concurrent chemo-radiotherapy in non-small cell lung cancer: preliminary clinical outcomes Karakaya, E.
 2013
 79 S1 p. S63-
1 p.
 artikel
38 212 Contemporary single institution experience in the surgical treatment of patients with small cell lung cancer Okiror, L.
 2013
 79 S1 p. S73-
1 p.
 artikel
39 181 CONVERT – the challenges of opening a multi-centre radiotherapy trial in the UK Faivre-Finn, C.
 2013
 79 S1 p. S62-
1 p.
 artikel
40 56 CT guided lung biopsy: A comparison of specialist registrar and consultant performed biopsies Kamil, A.
 2013
 79 S1 p. S19-
1 p.
 artikel
41 12 Current and ex-smokers with primary lung adenocarcinoma should be tested for EGFR mutation Clark, C.
 2013
 79 S1 p. S4-S5
2 p.
 artikel
42 205 90-day mortality after surgery for lung cancer – An analysis of the National Lung Cancer Audit Powell, H.A.
 2013
 79 S1 p. S71-
1 p.
 artikel
43 38 Delivering chemotherapy for lung cancer in the octogenarian patient: The Northern Centre for Cancer Care experience Graham, J.
 2013
 79 S1 p. S13-
1 p.
 artikel
44 104 Development of a pathway for management of hoarse voice from vocal cord paralysis in lung cancer Haslop, C.
 2013
 79 S1 p. S36-
1 p.
 artikel
45 4 DHMEQ, an NFkB inhibitor, inhibits cell proliferation and induces apoptosis in cisplatin resistant NSCLC Heavey, S.
 2013
 79 S1 p. S2-
1 p.
 artikel
46 65 Diagnosis of peripheral lung lesions using new virtual bronchoscopic navigation system Honda, H.
 2013
 79 S1 p. S22-
1 p.
 artikel
47 103 Do treatment decisions made at lung cancer multi-disciplinary team meetings (MDTs) reflect the actual treatment given in practice? Pemberton, L.
 2013
 79 S1 p. S36-
1 p.
 artikel
48 199 Early experience of a digital chest drainage system in the management of patients with malignant pleural effusion Morcos, K.H.K.
 2013
 79 S1 p. S69-
1 p.
 artikel
49 179 Early outcome in patients with early stage non-small cell lung cancer treated with stereotactic body radiotherapy (Cyberknife): Mount Vernon Cancer Centre experience Dubash, S.
 2013
 79 S1 p. S61-S62
2 p.
 artikel
50 69 EBUS-TBNA in the diagnosis of non-primary lung cancers Evison, M.
 2013
 79 S1 p. S24-
1 p.
 artikel
51 16 EGFR mutational analysis for adenocarcinoma of the lung; outcome by mutation since the introduction of routine molecular testing in one cancer network Okines, A.F.C.
 2013
 79 S1 p. S6-
1 p.
 artikel
52 24 EGFR testing in NSCLC. The Edinburgh Cancer Centre experience of the first 100 tested McGoldrick, T.
 2013
 79 S1 p. S8-S9
2 p.
 artikel
53 1 Elucidating the role of inflammatory mediators in cisplatin resistant NSCLC Baird, A.M.
 2013
 79 S1 p. S1-
1 p.
 artikel
54 9 Elucidating the role of the NFkB pathway in cisplatin resistant NSCLC Godwin, P.
 2013
 79 S1 p. S3-S4
2 p.
 artikel
55 107 Emergency admissions of lung cancer patients to a West Midlands hospital: causes and outcomes Palethorpe, M.
 2013
 79 S1 p. S37-
1 p.
 artikel
56 201 En-bloc chest wall VATS lobectomy – pushing the boundaries in the UK Stamenkovic, S.A.
 2013
 79 S1 p. S69-
1 p.
 artikel
57 68 Endobronchial ultrasound in the diagnosis of malignant intra-parenchymal lung lesions – a tertiary centre experience over 2.5 years Evison, M.
 2013
 79 S1 p. S23-S24
2 p.
 artikel
58 122 E&N Herts and lung cancer patient experience Dockree, E.
 2013
 79 S1 p. S42-
1 p.
 artikel
59 22 Epidermal growth factor receptor (EGFR) mutation testing in non small cell lung cancer – the New Cross Hospital experience Dunphy, L.
 2013
 79 S1 p. S8-
1 p.
 artikel
60 27 Erlotinib – how does it fare in an unselected population? An NHS Tayside experience Johnstone, J.
 2013
 79 S1 p. S9-
1 p.
 artikel
61 86 Evaluating BMS-777607 as a candidate therapeutic agent in malignant pleural mesothelioma O'Byrne, K.J.
 2013
 79 S1 p. S30-
1 p.
 artikel
62 133 Evaluating peer support in lung cancer support group Clayton, K.
 2013
 79 S1 p. S45-
1 p.
 artikel
63 55 Evaluation of an expedited referral pathway for suspected lung cancer de Fonseka, D.
 2013
 79 S1 p. S18-S19
2 p.
 artikel
64 168 Evaluation of quality of life in patients with primary and metastatic lung cancer following radiofrequency ablation Beeson, J.
 2013
 79 S1 p. S57-
1 p.
 artikel
65 45 Experience of multiple lines of systemic therapy in non-small cell lung cancer (NSCLC) at University Hospitals of Leicester Plant, R.
 2013
 79 S1 p. S15-
1 p.
 artikel
66 200 Experience with a digital chest drainage suction system (Thopaz) in the management of patients with malignant chest disease Morcos, K.
 2013
 79 S1 p. S69-
1 p.
 artikel
67 87 Expression of SDHB in malignant pleural mesothelioma Jennings, C.J.
 2013
 79 S1 p. S30-
1 p.
 artikel
68 60 Facilitating discussions of difficult cases at lung cancer MDTs – can the SUV of the primary tumour and lymph nodes be of any help? Evison, M.
 2013
 79 S1 p. S20-S21
2 p.
 artikel
69 57 18-FDG PET scanning in pulmonary carcinoid tumours Greenwood, A.J.
 2013
 79 S1 p. S19-S20
2 p.
 artikel
70 110 Follow up after resection of lung cancer: a survey of surgical practice in the UK and Ireland Greenwood, A.J.
 2013
 79 S1 p. S38-
1 p.
 artikel
71 35 G-CSF improves the safety of adjuvant chemotherapy with cisplatin and vinorelbine in resected non small cell lung cancer (NSCLC): closing the audit loop Chiramel, J.
 2013
 79 S1 p. S12-
1 p.
 artikel
72 25 Gefitinib in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-TK mutation – North Trent Cancer Network experience Nugent, L.
 2013
 79 S1 p. S9-
1 p.
 artikel
73 83 HDAC expression levels may play a role in cisplatin resistant MPM Baird, A.M.
 2013
 79 S1 p. S29-
1 p.
 artikel
74 207 Higher resection rates in non-small cell lung cancer are associated with better survival Beckett, P.
 2013
 79 S1 p. S71-
1 p.
 artikel
75 21 High sensitivity detection of epidermal growth factor receptor (EGFR) T790M mutants in non-small-cell lung cancer Tracey, J.
 2013
 79 S1 p. S7-S8
2 p.
 artikel
76 47 How are we doing? Clinical audit of patient survival and toxicities following adjuvant chemotherapy for non-small cell lung cancer in NHS Tayside 2005–2010 Costantino, S.
 2013
 79 S1 p. S16-
1 p.
 artikel
77 174 How much occult nodal disease are we missing with stereotactic radiotherapy for NSCLC? Robson, J.M.
 2013
 79 S1 p. S59-S60
2 p.
 artikel
78 191 Hyponatraemia secondary to SIADH in small cell lung cancer treated with tolvaptan Pothina, N.P.
 2013
 79 S1 p. S66-
1 p.
 artikel
79 118 I am dying of mesothelioma Davies, C.A.
 2013
 79 S1 p. S41-
1 p.
 artikel
80 5 IL-23R is expressed and regulated epigenetically in non small cell lung cancer Baird, A.M.
 2013
 79 S1 p. S2-
1 p.
 artikel
81 206 Impact of surgical attendance on referral for thoracic surgery Bogdan, C.
 2013
 79 S1 p. S71-
1 p.
 artikel
82 116 Improving the surgical patient pathway: A multidisciplinary approach Draffan, J.
 2013
 79 S1 p. S40-
1 p.
 artikel
83 10 Incidence of mutations in the epidermal growth factor receptor (EGFR) in Wrexham area patients with metastatic and locally advanced non-sqamous cell lung cancer Gostage, A.
 2013
 79 S1 p. S4-
1 p.
 artikel
84 101 Incidental discovery is the prevalent referral pathway to surgery for early stage lung cancer Brazil, S.V.
 2013
 79 S1 p. S35-
1 p.
 artikel
85 88 Inflammation-based prognostic biomarkers in patients with malignant pleural mesothelioma in the West of Scotland Tsim, S.
 2013
 79 S1 p. S31-
1 p.
 artikel
86 82 Inhibition of RON (MST1R) induces apoptosis and decreases the cellular migration and proliferation capacity of mesothelioma cells Baird, A.M.
 2013
 79 S1 p. S29-
1 p.
 artikel
87 106 Initial hospital presentation and outcome in patients diagnosed with thoracic malignancy Murukesh, N.
 2013
 79 S1 p. S37-
1 p.
 artikel
88 105 Integration of palliative medicine into a combined lung cancer service Mason, L.D.
 2013
 79 S1 p. S36-S37
2 p.
 artikel
89 162 Intensity modulated radiotherapy (IMRT) in locally advanced non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): Analysis of survival and toxicity outcomes McCloskey, P.
 2013
 79 S1 p. S55-S56
2 p.
 artikel
90 51 Intensive systemic treatment approach may be beneficial in advanced non-small cell lung cancer (NSCLC) Sharma, A.
 2013
 79 S1 p. S17-
1 p.
 artikel
91 198 Is cytological examination of pleural fluid obtained at VATS for suspected malignant pleural effusion useful? Campbell, A.M.
 2013
 79 S1 p. S68-S69
2 p.
 artikel
92 138 Is neuromuscular electrical stimulation (NMES) an acceptable and feasible exercise intervention for patients with non-small cell lung cancer (NSCLC) receiving palliative chemotherapy? Preliminary results from the NCRI NMES trial Byrne, A.
 2013
 79 S1 p. S46-S47
2 p.
 artikel
93 161 Isotoxic radiotherapy for non-small cell lung cancer: is intensity modulated radiotherapy (IMRT) the answer? Warren, M.
 2013
 79 S1 p. S55-
1 p.
 artikel
94 59 Is PET-CT overstaging lung cancer in Essex? Powrie, D.J.
 2013
 79 S1 p. S20-
1 p.
 artikel
95 63 Is PET-CT sufficient to exclude asymptomatic brain metastases prior to radical surgical treatment for lung cancer? Baldwin, D.R.
 2013
 79 S1 p. S21-S22
2 p.
 artikel
96 77 Is plasma fibrinogen a novel independent prognostic factor in patients undergoing surgery for non-small cell lung cancer? George, R.S.
 2013
 79 S1 p. S27-
1 p.
 artikel
97 85 KAT5 and KDM6B may be candidate therapeutic targets in malignant pleural mesothelioma Gao, Y.
 2013
 79 S1 p. S30-
1 p.
 artikel
98 49 Large-cell neuroendocrine carcinoma (LCNEC): a review of experience with adjuvant chemotherapy at Wythenshawe Hospital Leyakathali Khan, S.
 2013
 79 S1 p. S16-S17
2 p.
 artikel
99 170 Lung ART: Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement Faivre-Finn, C.
 2013
 79 S1 p. S58-
1 p.
 artikel
100 143 Lung Cancer Assistant: a decision support application in lung cancer care Sesen, B.
 2013
 79 S1 p. S48-
1 p.
 artikel
101 14 Lung cancer diagnosis, EGFR testing and their implications Lodge, K.
 2013
 79 S1 p. S5-
1 p.
 artikel
102 125 Lung Cancer Patient Small Grant Fund review Dornan, L.
 2013
 79 S1 p. S42-S43
2 p.
 artikel
103 147 Lung cancer survival in different ethnic groups in Leeds: Results of a 16,000 patient population study Afshar, M.
 2013
 79 S1 p. S49-S50
2 p.
 artikel
104 32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations O'Byrne, K.J.
 2013
 79 S1 p. S11-
1 p.
 artikel
105 93 Malignant pleural mesothelioma treated with pemetrexed and cisplatin: a therapy study Davis, L.
 2013
 79 S1 p. S32-S33
2 p.
 artikel
106 194 Management of indeterminate lung nodules in colorectal cancer Hunt, D.
 2013
 79 S1 p. S67-
1 p.
 artikel
107 202 Management of stage I and II non-small cell lung cancer at Plymouth Hospitals NHS Trust Iyer, S.
 2013
 79 S1 p. S70-
1 p.
 artikel
108 149 Management of thymomas; a case series review from the North of England Cancer Network (south) Woolcock, S.
 2013
 79 S1 p. S50-S51
2 p.
 artikel
109 124 Maximising financial aid for patients in a thoracic oncology clinic in Merthyr Tydfil. The effect of a clinic-based Welfare Rights Officer Tanguay, J.S.
 2013
 79 S1 p. S42-
1 p.
 artikel
110 74 Medical thoracoscopy and malignant pleural effusions (MPE) – 40 months on in the Cambridge pleural unit Chatterji, S.
 2013
 79 S1 p. S26-
1 p.
 artikel
111 136 Meeting the information needs of lung cancer patients and carers. Review and update of Lung Cancer – Answering your Questions booklet Dickson, J.L.
 2013
 79 S1 p. S46-
1 p.
 artikel
112 119 Mesothelioma – a Welsh patient experience Horne, N.
 2013
 79 S1 p. S41-
1 p.
 artikel
113 90 Mesothelioma in Sunderland; epidemiology and impact of carboplatin–pemetrexed chemotherapy on survival Pollock, S.
 2013
 79 S1 p. S31-S32
2 p.
 artikel
114 91 Mesothelioma of pleural space diagnosed at awake sedation thoracoscopy – a service assessment Tarique, S.
 2013
 79 S1 p. S32-
1 p.
 artikel
115 2 MicroRNA profiling and cisplatin–DNA interactions in an isogenic model of cisplatin resistant NSCLC cell lines Barr, M.P.
 2013
 79 S1 p. S1-
1 p.
 artikel
116 53 Miss rate of lung cancer on the chest radiograph in the Belfast Trust 2011 Neeson, D.
 2013
 79 S1 p. S18-
1 p.
 artikel
117 54 MyLungRisk calculator: a user-friendly, web-based questionnaire for risk prediction of lung cancer based on the validated Liverpool Lung Project model Field, J.K.
 2013
 79 S1 p. S18-
1 p.
 artikel
118 117 National Lung Cancer Forum For Nurses Supported By Lilly Project 2011/2012 – Developing guidance for the supportive and palliative care of lung cancer and mesothelioma patients and their carers Richardson, A.
 2013
 79 S1 p. S40-S41
2 p.
 artikel
119 132 NHS Lanarkshire Lung Cancer Information & Support Sessions: a service review – A viable & modern approach in patient support Irvine, L.
 2013
 79 S1 p. S45-
1 p.
 artikel
120 130 NHS Lanarkshire Lung Oncology Service: a nurse led erlotinib toxicity assessment clinic within the lung oncology clinic Irvine, L.
 2013
 79 S1 p. S44-
1 p.
 artikel
121 15 Non-invasive KRAS and EGFR mutation testing of primary lung cancer via peripheral blood circulating tumour cells Freidin, M.B.
 2013
 79 S1 p. S5-S6
2 p.
 artikel
122 123 Nutritional reassessment and dietary support of thoracic oncology outpatients is a ‘MUST’ Howell, G.H.
 2013
 79 S1 p. S42-
1 p.
 artikel
123 146 Offering quantitative prognosis to lung cancer patients Johnston, R.
 2013
 79 S1 p. S49-
1 p.
 artikel
124 98 Oncolytic virus therapy for mesothelioma – a phase I trial of intrapleural seprehvir Woll, P.J.
 2013
 79 S1 p. S34-
1 p.
 artikel
125 128 Oral vinorelbine eliminates risk of phlebitis and saves “chair time” in a busy chemotherapy unit Jessop, S.
 2013
 79 S1 p. S44-
1 p.
 artikel
126 164 Outcome of whole brain radiotherapy (WBRT) in patients with inoperable brain metastases from non-small cell lung cancer (NSCLC) Namelo, W.C.
 2013
 79 S1 p. S56-
1 p.
 artikel
127 33 Outcomes of patients undergoing adjuvant platinum–vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC) Pender, A.
 2013
 79 S1 p. S12-
1 p.
 artikel
128 36 Palliative chemotherapy with carboplatin and oral vinorelbine in advanced/metastatic non-small cell lung cancer – North Trent Cancer Network experience Alzouebi, M.
 2013
 79 S1 p. S12-S13
2 p.
 artikel
129 37 Palliative chemotherapy with fractionated carboplatin and vinorelbine for elderly and poor performance status patients with NSCLC Datta, S.
 2013
 79 S1 p. S13-
1 p.
 artikel
130 167 Palliative radiotherapy for lung cancer – A prospective study on quality of life Eng, L.
 2013
 79 S1 p. S57-
1 p.
 artikel
131 166 Palliative whole brain radiotherapy in primary lung cancer – Are we using too much? Buckley, H.C.
 2013
 79 S1 p. S57-
1 p.
 artikel
132 113 Patient education programme for patients undergoing a lung resection Dixon, S.
 2013
 79 S1 p. S39-
1 p.
 artikel
133 120 Patient journey interviews Dixon, S.
 2013
 79 S1 p. S41-
1 p.
 artikel
134 73 Patient perceived discomfort at awake sedation thoracoscopy Tarique, S.
 2013
 79 S1 p. S25-S26
2 p.
 artikel
135 210 Patient quality of life improves with introduction of a Rehabilitation for Operated lung Cancer (ROC) programme: evaluation of patient reported outcome measures Wotton, R.
 2013
 79 S1 p. S72-S73
2 p.
 artikel
136 108 Patient satisfaction survey for one stop lung cancer clinic Gupta, T.
 2013
 79 S1 p. S37-S38
2 p.
 artikel
137 71 Patient satisfaction with bronchoscopy and EBUS Ghafur, S.
 2013
 79 S1 p. S25-
1 p.
 artikel
138 211 Patient satisfaction with day of admission surgery Johnston, L.
 2013
 79 S1 p. S73-
1 p.
 artikel
139 72 Patient satisfaction with thoracoscopy Ghafur, S.
 2013
 79 S1 p. S25-
1 p.
 artikel
140 209 Patients undergoing lung cancer surgery and allied healthcare professionals benefit from patient information in the form of a DVD Wotton, R.
 2013
 79 S1 p. S72-
1 p.
 artikel
141 142 Patterns of presentation of venous thromboembolism (VTE) in lung cancer: experience from a cancer unit Jeffs, Y.
 2013
 79 S1 p. S48-
1 p.
 artikel
142 66 Physician-led thoracic ultrasound guided lung biopsies in the diagnosis of lung cancer Thomas, J.J.
 2013
 79 S1 p. S22-S23
2 p.
 artikel
143 8 PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC Heavey, S.
 2013
 79 S1 p. S3-
1 p.
 artikel
144 97 PIT: A Phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention Faivre-Finn, C.
 2013
 79 S1 p. S34-
1 p.
 artikel
145 169 PORT Meta-Analysis reprise: modern 3-D radiation treatment planning exposes deficiencies in PORT Meta-Analysis Stevens, C.W.
 2013
 79 S1 p. S57-S58
2 p.
 artikel
146 23 Pragmatic approach to EGFR mutation testing in advanced lung cancer: a single institution's experience Abdul, N.
 2013
 79 S1 p. S8-
1 p.
 artikel
147 3 Pre-therapeutic ex-vivo repair kinetics of cisplatin–DNA-adducts in circulating tumor cells (CTC) as platinum resistance test Nell, I.
 2013
 79 S1 p. S2-
1 p.
 artikel
148 159 Prospective data of continuous hyperfractionated accelerated radiotherapy (CHART) for non-small cell lung cancer (NSCLC) in North East cancer centre McFetrich, C.
 2013
 79 S1 p. S54-
1 p.
 artikel
149 192 Pulmonary metastasectomy in colorectal cancer (PulMiCC) – A surgeon friendly randomised trial design Treasure, T.
 2013
 79 S1 p. S66-S67
2 p.
 artikel
150 193 Pulmonary metastasectomy in colorectal cancer: working towards a consensus. A survey of PulMiCC UK Trial Centre principal investigators and MDTs within a cancer network George, R.S.
 2013
 79 S1 p. S67-
1 p.
 artikel
151 79 Pulmonary neuroendocrine tumours: diagnostic and prognostic factors Dunphy, L.
 2013
 79 S1 p. S28-
1 p.
 artikel
152 165 Quality of life after treatment for brain metastases from NSCLC: An update on the Medical Research Council QUARTZ trial Mulvenna, P.
 2013
 79 S1 p. S56-S57
2 p.
 artikel
153 182 Radical concurrent chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC) Stilwell, C.H.
 2013
 79 S1 p. S62-S63
2 p.
 artikel
154 48 Radical management of inoperable stage III non-small cell lung cancer (NSCLC) in the Greater Manchester and Cheshire Cancer Network (GMCCN) – an analysis of patient eligibility and justification for treatment Roberts, H.
 2013
 79 S1 p. S16-
1 p.
 artikel
155 157 Radical radiotherapy for NSCLC in the very elderly: Can failure to tolerate treatment be predicted? Chaudhury, S.
 2013
 79 S1 p. S53-
1 p.
 artikel
156 154 Radiotherapy for non-small cell lung cancer: From 3D conformal to 4D to stereotactic ablative radiotherapy (SABR) in a year – the Birmingham experience Meade, S.
 2013
 79 S1 p. S52-
1 p.
 artikel
157 163 REST: A randomised trial comparing prophylactic cranial irradiation (PCI) to PCI + thoracic radiotherapy in extensive stage small cell lung cancer (ES-SCLC) Faivre-Finn, C.
 2013
 79 S1 p. S56-
1 p.
 artikel
158 28 Retrospective evaluation of 200 patients managed with second-line erlotinib at St James's Institute of Oncology, Leeds Murray, L.J.
 2013
 79 S1 p. S10-
1 p.
 artikel
159 44 Review of the pemetrexed–cisplatin chemotherapy in non-squamous non-small cell lung cancer in Royal Shrewsbury Hospital Boon, C.
 2013
 79 S1 p. S15-
1 p.
 artikel
160 121 Setting up a mesothelioma patient carer support group across a cancer network Bolton, S.
 2013
 79 S1 p. S41-S42
2 p.
 artikel
161 61 Should all patients with suspected lung cancer requiring endoscopic staging of the mediastinum undergo PET-CT first? Evison, M.
 2013
 79 S1 p. S21-
1 p.
 artikel
162 95 Single centre experience of the use of vinorelbine soft capsules as second-line therapy for patients with malignant pleural mesothelioma (MPM) Barfoot, J.
 2013
 79 S1 p. S33-
1 p.
 artikel
163 144 Smoking cessation advice and help for lung cancer patients – an audit of current practice Eng, L.
 2013
 79 S1 p. S49-
1 p.
 artikel
164 78 Stage I and II lung cancer audit and accuracy of data submission Naseer, R.
 2013
 79 S1 p. S27-S28
2 p.
 artikel
165 64 Staging lung cancer: the additional value of contrast-enhanced head CT with PET-CT Lee, J.S.
 2013
 79 S1 p. S22-
1 p.
 artikel
166 109 Standards of lung cancer management in a South East England trust Montefort, M.Z.
 2013
 79 S1 p. S38-
1 p.
 artikel
167 178 Stereotactic ablative radiotherapy (SABR) for early stage, medically inoperable NSCLC: initial outcomes from 3 years experience at James Cook University Hospital (JCUH), Middlesbrough Carr, R.
 2013
 79 S1 p. S61-
1 p.
 artikel
168 171 Stereotactic ablative radiotherapy (SABR) in medically inoperable early stage non-small cell lung cancer (NSCLC): A single tertiary UK centre experience Yip, C.
 2013
 79 S1 p. S58-
1 p.
 artikel
169 180 Stereotactic ablative radiotherapy utilising volumetric modulated arc therapy Harrow, S.
 2013
 79 S1 p. S62-
1 p.
 artikel
170 141 Strategies employed to manage massive haemoptysis in patients with incurable lung cancer, results of an anonymous survey Davies, S.
 2013
 79 S1 p. S47-S48
2 p.
 artikel
171 137 Supporting lung cancer specialist nurses. Providing accredited training to Roy Castle affiliated group facilitators Cochrane, B.
 2013
 79 S1 p. S46-
1 p.
 artikel
172 96 Surgical and large bore pleural interventions in malignant pleural mesothelioma and radiotherapy trial (The SMART Trial) Clive, A.O.
 2013
 79 S1 p. S33-
1 p.
 artikel
173 115 Surgical lung cancer specialist nurse in accordance with NICE standard Trinder, J.
 2013
 79 S1 p. S40-
1 p.
 artikel
174 213 Surgical management of primary tracheal tumours: A single institutional experience Balasubramanian, V.
 2013
 79 S1 p. S73-S74
2 p.
 artikel
175 203 Surgical resection in low stage non-small cell lung cancer within the North Tees and Hartlepool NHS Foundation Trust Taylor, S.L.
 2013
 79 S1 p. S70-
1 p.
 artikel
176 134 Survey of the non-medical prescribers of the National Lung Cancer Forum for Nurses White, J.
 2013
 79 S1 p. S45-
1 p.
 artikel
177 92 Survival of patients with advanced mesothelioma treated with cisplatin and pemetrexed combination Hirst, J.
 2013
 79 S1 p. S32-
1 p.
 artikel
178 139 Syndrome of inappropriate antidiuretic hormone secretion and treatment with tolvaptan – a case series Vere, J.
 2013
 79 S1 p. S47-
1 p.
 artikel
179 50 Systemic therapy in the management of non small cell lung cancer (NSCLC): The real world experience Lewis, A.
 2013
 79 S1 p. S17-
1 p.
 artikel
180 195 Talc pleurodesis or IPC for malignant pleural effusion. Is it TIME to change? Sharkey, A.J.
 2013
 79 S1 p. S67-
1 p.
 artikel
181 84 Tamoxifen induced signalling in the suppression of malignant pleural mesothelioma cell growth Jennings, C.J.
 2013
 79 S1 p. S29-S30
2 p.
 artikel
182 7 Targeting neuropilin-1 in non-small cell lung cancer Barr, M.P.
 2013
 79 S1 p. S3-
1 p.
 artikel
183 89 Targeting nuclear factor-kappa B in malignant pleural mesothelioma Gately, K.
 2013
 79 S1 p. S31-
1 p.
 artikel
184 31 Testing for association between TPMT, COMT and NOX3 variants and the onset of ototoxicity in lung cancer patients treated with platinum chemotherapy Corrigan, A.
 2013
 79 S1 p. S11-
1 p.
 artikel
185 18 Testing for EGFR mutations in patients with non-small-cell lung cancer at Musgrove Park Hospital, Taunton Saxby, H.
 2013
 79 S1 p. S6-S7
2 p.
 artikel
186 58 Test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumours Pattenden, H.
 2013
 79 S1 p. S20-
1 p.
 artikel
187 100 The effect of the National Lung Cancer Awareness Campaign on referrals to the Rapid Access Lung Clinic Spiegler, T.
 2013
 79 S1 p. S35-
1 p.
 artikel
188 102 The importance of clinical triage of lung cancer referrals – a retrospective audit Morgan, A.J.
 2013
 79 S1 p. S35-S36
2 p.
 artikel
189 145 The importance of occupation in lung carcinoma Knight, R.
 2013
 79 S1 p. S49-
1 p.
 artikel
190 189 The incidence of hyponatraemia in small cell lung cancer: prognostic and predictive potential in a retrospective single centre analysis Walter, H.S.
 2013
 79 S1 p. S65-S66
2 p.
 artikel
191 176 The introduction of stereotactic ablative radiotherapy increases overall radical treatment rates for stage I lung cancer but does not reduce surgical resection rates – a single centre study Cheyne, L.
 2013
 79 S1 p. S60-
1 p.
 artikel
192 160 The largest single centre series using hypofractionated radical radiotherapy treatment for NSCLC (non-small cell lung cancer) in the very elderly McPartlin, A.J.
 2013
 79 S1 p. S54-
1 p.
 artikel
193 52 The National Lung Cancer Awareness Campaign – a study to assess the impact on lung cancer detection and staging within a busy UK hospital trust Law, H.
 2013
 79 S1 p. S17-S18
2 p.
 artikel
194 67 Therapeutic flexible bronchoscopy in lung malignancy – results from a prospective registry at Papworth Hospital Roy, K.
 2013
 79 S1 p. S23-
1 p.
 artikel
195 114 The role of acupuncture in the management of post-thoracotomy pain: description and evaluation of an acupuncture service in lung cancer survivorship Noble, S.
 2013
 79 S1 p. S39-S40
2 p.
 artikel
196 135 The role of non-medical prescribing Draffan, J.
 2013
 79 S1 p. S45-S46
2 p.
 artikel
197 158 The role of primary chemotherapy prior to continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of non-small cell lung carcinoma at Nottingham University Hospital Knox, C.E.
 2013
 79 S1 p. S53-S54
2 p.
 artikel
198 127 The role of the LCNS in oncology follow up, how a patient booklet has been devised Savory, S.
 2013
 79 S1 p. S43-
1 p.
 artikel
199 112 The surgical patient – identifying factors that may predict a difficult pathway and transition into survivorship Peel, T.
 2013
 79 S1 p. S39-
1 p.
 artikel
200 81 The uniqueness of the United Kingdom Lung Cancer Screening trial (UKLS) – a population screening study McRonald, F.
 2013
 79 S1 p. S28-S29
2 p.
 artikel
201 70 The University Hospital South Manchester EBUS-TBNA Service – Performance Report 2010–2012 Evison, M.
 2013
 79 S1 p. S24-S25
2 p.
 artikel
202 29 The use of erlotinib as second line treatment in patients with non-small cell lung carcinoma (NSCLC) in Birmingham. Does EGFR play a role? Reeve, N.
 2013
 79 S1 p. S10-
1 p.
 artikel
203 41 Thirty-day lung cancer mortality: a retrospective review of patients in the North Trent Cancer Network Bowen, K.
 2013
 79 S1 p. S14-
1 p.
 artikel
204 188 Three years experience of chemotherapy for small cell lung cancer at a tertiary referral centre Hough, N.
 2013
 79 S1 p. S65-
1 p.
 artikel
205 187 Time intervals between diagnosis and treatment in the management of small cell lung cancer and their impact on prognosis Walter, H.S.
 2013
 79 S1 p. S65-
1 p.
 artikel
206 190 Tolvaptan – cost effective treatment of SIADH in malignancies Shakher, J.
 2013
 79 S1 p. S66-
1 p.
 artikel
207 184 Toxicities and compliance to treatment in locally advanced non-small cell lung cancer (LA-NSCLC) treated with concurrent chemoradiotherapy (cCTRT) at the Christie NHS Foundation Trust Mehmood, Q.
 2013
 79 S1 p. S63-S64
2 p.
 artikel
208 129 Treating non small cell lung cancer with erlotinib: the Nurse Led clinic experience Compton, S.
 2013
 79 S1 p. S44-
1 p.
 artikel
209 151 Tumor volume versus outcome in non-small cell lung cancer – tertiary care centre experience Roshan, V.
 2013
 79 S1 p. S51-
1 p.
 artikel
210 197 Tunnelled intrapleural catheters (TIPC) for patients with recurrent malignant pleural effusion: Experience from the North East of Scotland Mahendra, P.
 2013
 79 S1 p. S68-
1 p.
 artikel
211 62 Two year results of supraclavicular lymph node FNA for lung cancer Tiwari, S.
 2013
 79 S1 p. S21-
1 p.
 artikel
212 75 Unilateral small pleural effusions adjacent to primary lung tumours – malignant or reactive? Evison, M.
 2013
 79 S1 p. S26-S27
2 p.
 artikel
213 43 Use of first line maintenance chemotherapy with pemetrexed in patients with non squamous non small cell lung cancer – North Trent Cancer Network experience Stansfield, R.
 2013
 79 S1 p. S15-
1 p.
 artikel
214 152 Variation in maximal oesophageal dose with respiration during radical radiotherapy for NSCLC Illsley, M.C.
 2013
 79 S1 p. S51-
1 p.
 artikel
215 42 10 year retrospective review of single agent chemotherapy as first line treatment in advanced non-small cell lung cancer (NSCLC) in Princess Margaret Hospital: Assessment of efficacy and prognostic factors Martin, P.
 2013
 79 S1 p. S14-S15
2 p.
 artikel
                             215 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland